Search company, investor...

Sortina Pharma

Stage

Seed VC | Alive

About Sortina Pharma

Sortina Pharma is a Swedish company with know-how from the University of Gothenburg, focusing on developing more effective therapies against cancer. The company’s first-in-class drug candidate has the unique potential to eliminate the aggressive cancer cells with the use of small molecules targeting sortilin and thereby reducing metastasis and recurrence of cancer. First indication is triple negative breast cancer, with the potential to build a portfolio with several other cancer indications. Sortina Pharma´s pharmaceutical has the potential to cure patients from cancer and take cancer treatment to the next level.

Headquarters Location

Erik Dahlbergsgatan 11A

Gothenburg, 411 26,

Sweden

Missing: Sortina Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Sortina Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Sortina Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sortina Pharma is included in 2 Expert Collections, including Women's Health & Wellness.

W

Women's Health & Wellness

1,482 items

Startups focused on providing products and services catering to women's health and wellbeing.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Latest Sortina Pharma News

Sortina Pharma AB has appointed Sara Rhost as CEO, with start from 1th of December 2021

Nov 16, 2021

.............................................................. Sara has a doctoral degree in immunology from Gothenburg University and has been managing and driving the sortilin-project from research into product development. She has extensive experience in cancer research and has been one of the lead scientists for the sortilin-project initiated at the University of Gothenburg. She has co-founded Sortina Pharma together with professor Göran Landberg and GU Ventures in 2020. There are several cancer types that have increased expression of sortilin, we are initially aiming for a subgroup of 20% of breast cancer patients who have increased sortilin-levels and related thereto increased risk of metastatic cancer. Sortina Pharma has reached several milestones in developing a first in class novel anti-sortilin binding small molecules for the treatment of metastatic cancer. We are now very satisfied that we have recruited Sara as CEO to build Sortina Pharma and to accelerate the product development, with initial goals to select a CD and document effects in patients. GU Ventures, as one of the owners of Sortina Pharma, want to welcome Sara Rhost as CEO for Sortina Pharma. ”We are pleased that we have recruited Sara. As CEO she will build Sortina Pharma by accelerating progress towards our initial goal of selecting a CD and documenting its effects in patients”.- Anders Waas, business developer, GU Ventures. From the left: Göran Landberg, Sara Rhost, Thomas Olsson, Anders Waas, Tommy Abrahamsson, Christer Westerlund and Jesper Dahlberg. About Sortina Pharma Sortina Pharma is a Swedish company with know-how from the University of Gothenburg, focusing on developing more effective therapies against cancer. The company’s first-in-class drug candidate has the unique potential to eliminate the aggressive cancer cells with the use of small molecules targeting sortilin and thereby reducing metastasis and recurrence of cancer. First indication is triple negative breast cancer, with the potential to build a portfolio with several other cancer indications. Sortina Pharma´s pharmaceutical has the potential to cure patients from cancer and take cancer treatment to the next level. Ämnen

Sortina Pharma Frequently Asked Questions (FAQ)

  • Where is Sortina Pharma's headquarters?

    Sortina Pharma's headquarters is located at Erik Dahlbergsgatan 11A, Gothenburg.

  • What is Sortina Pharma's latest funding round?

    Sortina Pharma's latest funding round is Seed VC.

  • Who are the investors of Sortina Pharma?

    Investors of Sortina Pharma include GU Ventures and EIR Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.